More medtech IPOs axed
This article was originally published in Clinica
Executive Summary
Two further medical device firms have terminated their IPOs on the Nasdaq stock exchange, bringing the total number of listing cancellations for medtech firms so far this month to four. Organ transportation firm TransMedics (Andover, Massachusetts) and healthcare information technology specialist Epocrates (San Mateo, California) both filed withdrawal requests with the Securities and Exchange Commission on December 12. Both firms cited unfavourable market conditions as the reason for the withdrawals. Earlier this month, ear, nose and throat company Acclarent and molecular diagnostics firm Osmetech also cancelled their IPOs (see Clinica No 1329, p 17).
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals